Profil & Biographie

Dr. Eric Campeau, PhD.

DIRIGEANT EN RECHERCHE TRANSLATIONNELLE
CONSEILLER STRATÉGIQUE

Le Dr Éric Campeau est un dirigeant en sciences translationnelles qui possède plus de 30 ans d’expérience en recherche et 15 ans à des postes de direction dans l’industrie. Il se spécialise dans l’établissement de liens entre la recherche fondamentale en biologie et les premières étapes du développement clinique. Son parcours témoigne de sa capacité à transformer des connaissances biologiques complexes en programmes de développement thérapeutique susceptibles d’attirer des investissements et de créer une valeur distinctive pour les patients et les investisseurs.

Domaines d’expertise

  • Expertise thérapeutique: oncologie, inflammation, fibrose et maladies cardiométaboliques, avec une expertise particulière dans les interactions entre les cellules malades, le stroma et le microenvironnement immunitaire.
  • Médecine personnalisée et approches omiques: Expertise en transcriptomique et génomique, caractérisation des changements génétiques et épigénétiques et des voies signalitiques associées aux maladies pour identifier les patients qui ont le plus de chances de bénificier de la thérapie.
  • Mécanismes d'action & différenciation: élucidation des mécanismes d’action, démonstration de l’engagement de la cible et analyse comparative des approches concurrentes afin de mettre en évidence les facteurs de différenciation du traitement.
  • Stratégie réglementaire et de portefeuille: gestion des interactions avec les organismes réglementaires et institutionnels afin d’obtenir leur appui à des plans d’essais cliniques innovants intégrant les biomarqueurs et les approches de médecine personnalisée.
  • Prise de parole en public et présentations scientifiques: conférencier et mentor, communication des concepts scientifiques complexes de façon claire, accessible et captivante auprès de publics scientifiques, d’investisseurs et du grand public. Révision et optimisation de présentations scientifiques pour renforcer la clarté des messages, la structure du contenu et leur impact.

Réalisations professionnelles et résultats

  • Financement Stratégique: contribution à l’obtention de plus de 50 M$ en financement stratégique, ainsi qu’à l'élargissement du portefeuille de programmes thérapeutiques de l'entreprise. Obtention également de plus de 450 000 $ en financement non-dilutif pour renforcer les capacités scientifiques de l'entreprise.
  • Avancement de Programmes Précliniques: progression réussie de plusieurs programmes en oncologie et dans les maladies cardiométaboliques jusqu’au stade d'acceptation de la demande IND.
  • Réussites Cliniques en Phases 1 & 2: direction du développement translationnel de traitements combinés aux traitements de référence, dans le cadre d’essais ayant atteint leurs critères de jugement principaux.
  • Partneriats & Innovation: Direction des travaux de recherche translationnelle et des présentations de données ayant permis de conclure des partenariats de grande valeur, incluant un accord clinique majeur avec une société pharmaceutique d'envergure ; inventeur sur 6 brevets et auteur de plus de 25 publications révisées par des pairs.

Formation & Leadership

  • PhD en Génétique Humaine - Université McGill.
  • Gestionnaire de Projets Professionnel (PMP) – Project Management Institute (PMI).
  • Certificat en Gestion Professionnelle, Spécialisation en Gestion Stratégique - Université de Calgary.
  • Réseau International: Mise en Place & Gestion de Collaborations avec > 12 Établissements Universitaires & Cliniques de Renommée Mondiale.
  • Prise de Parole en Public & Mentorat: Directeur de Secteur et Mentor Actif au sein de Toastmasters Inernational, accompagnant les membres dans le développement de leurs compétences en présentation publique & en leadership afin d'inspirer leurs auditoires.

Publications (lien vers PubMed)

  1. Pradhananga, D.Srinivasan, E.Campeau, M.Vidal, D.Labit, K.Frias Boligan, A.Brkovic, P.F.Truex, D.Odink, E.R. Gamazon, R.Shah, A.Sehnert, S.Das (2026). Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure. JACC Heart Fail. *Co-first author
  2. E.Campeau*, S.Pradhananga, D.Srinivasan, M.Vidal , D.Labit , K.Frias Boligan, A.Brkovic, P.F.Truex, D.Odink, E.R.Gamazon, R.Shah, A.Sehnert, S.Das (2025). THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure. In review. Preprint: https://www.researchsquare.com/article/rs-7539711/v1 *Corresponding author and co-first author.
  3. S.Shukla, D.Li, W.H.Cho, D.M.Schoeps, H.M.Nguyen, J.L.Conner, M.L.Roskes, A.Tehim, G.Bayshtok, M.R.Pachai, J.Yuan, N.A.Teri, E.Campeau, S.Attwell, P.Trojer, I.Ostrovnaya, A.Gopalan, E.Khurana, E.Corey, P.Chi, Y.Chen (2025). BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancer. J.Clin.Invest.;135(16):e180378.
  4. J.Wellbrock, L.Behrmann, J.Muschhammer, F.Modemann, K.Khoury, F.Brauneck, C.Bokemeyer, E.Campeau, W.Fiedler (2021). The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia. Ann.Hematol. 100(12):2933-2941.
  5. D.H.Kim, D.Sun, W.K.Storck, K.R.Welker Leng, C.Jenkins, D.J.Coleman, D.A.Sampson, X.Guan, A.Kumaraswamy, E.S.Rodansky, J.A.Urrutia, J.Schwartzman, C.Zhang, H.Beltran, M.P.Labrecque, C.Morrissey, J.M.Lucas, I.Coleman, P.S.Nelson, E.Corey, S.K.Handelman, J.Z.Sexton, R.Aggarwal, W.Abida , F.Y.Feng, E.J.Small, D.E.Spratt, A.Bankhead, A.Rao , E.M.Gesner, S.Attwell, S.Lakhotia, E.Campeau, J.A.Yates, Z.Xia, J.J.Alumkal (2021). BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin.Can.Res. 27(17):4923-4936.
  6. R.R.Aggarwal, M.T.Schweizer, D.M.Nanus, A.J.Pantuck, E.J.Heath, E.Campeau, S.Attwell, K.Norek, M.Snyder, L.Bauman, et al. (2020). A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin.Can.Res. 26, 5338-5347.
  7. S.V.Muralidharan, B.O.Einarsdottir, J.Bhadury, M.F.Lindberg, J.Wu, E.Campeau, R.O.Olofsson Bagge, U. Stierner, l.Ny, L.M.Nilsson, J.A.Nilsson (2017). BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death Dis, 8(12), e3177.
  8. C.L.Smith, T.D.Matheson, D.J.Trombly, X.Sun, E.Campeau, X.Han, J.R.Yates, 3rd, and P.D.Kaufman,(2014). A separable domain of the p150 subunit of human chromatin assembly factor-1 promotes protein and chromosome associations with nucleoli. Mol Biol Cell 25, 2866-2881.
  9. K.G.McLure, E.M.Gesner, L.Tsujikawa, O.A.Kharenko, S.Attwell S, E.Campeau, S.Wasiak, A.Stein, A.White, E.Fontano, R.K.Suto, N.C.Wong, G.S.Wagner, H.C.Hansen, P.R.Young. (2013). RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS ONE 8(12): e83190.
  10. E.Campeau*, S.Gobeil (2011). RNA interference in mammalian cells: behind the screen. Brief.Funct.Genomics. 10(4):215-26. *Co-corresponding author.
  11. F.Rodier, D.P.Muñoz, R.Teachenor, V.Chu, O.Le, D.Bhaumik, J.P.Coppé, E.Campeau, C.Beauséjour, S.H.Kim, A.R.Davalos, J.Campisi (2011). DNA-SCARS: Distinct Nuclear Structures that Sustain Damage-Induced Senescence Growth Arrest and Inflammatory Secretion. J.Cell.Sci. 124:68-81.
  12. A.V.Bazarov, M.van Sluis, C.Hines, E.Bassett, A.Beliveau, E.Campeau, R.Mukhopadhyay, W.J.Lee, S.Melodyev, Y.Zaslavsky, L.Lee, F.Rodier, A.Chicas, S.W.Lowe, J.Benhattar, B.Ren, J.Campisi, P.Yaswen (2010). P16INK4a Mediated suppression of telomerase in normal and malignant human breast cells. Aging Cell 9:736-746.
  13. E.Campeau*, V.E.Ruhl, F.Rodier, C.L.Smith, B.L.Rahmberg, J.O.Fuss, J.Campisi, P.Yaswen, P.K.Cooper, P.D.Kaufman (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE: 4(8): e6529. *Corresponding author.
  14. F.Rodier, J.P.Coppé, C.K.Patil, W.A.M.Hoeijmakers, D.P.Munoz, S.R.Raza, A.Freund, E.Campeau, A.R.Davalos, J.Campisi (2009). Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion. Nat.Cell Biol. 11(8):973-979.
  15. A.H.Sarker, S.E.Tsutakawa, S.Kostek, C.Ng, D.Shin, M.Peris, E.Campeau, E.Nogales, J.A. Tainer, P.K.Cooper (2005) RNA polymerase II transcription bubble recognition by XPG, CSB and TFIIH: Insights for transcription-coupled repair and Cockayne Syndrome. Mol Cell. 20(2):187-98.
  16. E.Campeau, L.R.Desviat, D.Leclerc, X.Wu, B.Perez, M.Ugarte, R.A.Gravel (2001a). Structure of the PCCA gene and distribution of mutations causing propionic acidemia. Mol Genet Metab 2001; 74(1-2):238-47.
  17. E.Campeau and R.A.Gravel (2001b). Expression in Escherichia coli of N- and C-terminally deleted human holocarboxylase synthetase. Influence of the N-terminus on biotinylation and identification of a minimum functional protein. J Biol Chem. Apr 13;276(15):12310-6.
  18. M.Ugarte, C.Pérez-Cerdá, P.Rodríguez-Pombo, L.R.Desviat, B.Pérez, E.Richard, S.Muro, E.Campeau, T.Ohura, R.A.Gravel (1999). An overview of mutations in the PCCA and PCCB genes causing propionic acidemia. Hum Mutat. 14(4):275-82.
  19. E.Campeau, L.Dupuis, A.Leon del Rio, R.A.Gravel (1999a). Coding sequence mutations in the alpha subunit of propionyl-CoA carboxylase in patients with propionic acidemia. Mol.Genet.Metab (67):11-22.
  20. E.Campeau, L.Dupuis, D.Leclerc, R.A.Gravel (1999b). Detection of a normally rare transcript in propionic acidemia patients with mRNA destabilizing mutations in the PCCA gene. Hum.Mol.Genet.8(1): 107-113.
  21. L.Dupuis, E.Campeau, D.Leclerc, R.A.Gravel (1999). Mechanism of biotin-responsiveness in biotin-responsive multiple carboxylase deficiency. Mol.Genet.Metab. 66:80-90.
  22. A.Wilson, D.Leclerc, F.Saberi, E.Campeau, H.Y.Hwang, B.Shane, J.A.Phillips, D.Soper-Rosenblatt, R.A.Gravel (1998). Functionally null mutations in patients with the CblG-variant form of methionine synthase deficiency. Am.J.Hum.Genet. 63(2):409-414.
  23. B.R.Akerman, M.R.Natowicz, M.M.Kaback, M.Loyer, E.Campeau, R.A.Gravel (1997). Novel mutations and DNA-based screening in non-Jewish carriers of Tay-Sachs disease. Am.J.Hum.Genet.60(5):1099-1106.
  24. D.Leclerc, E.Campeau, P.Goyette, C.E.Adjalla, B.Christensen, M.Ross, P.Eydoux, D.S.Rosenblatt, R.Rozen, R.A.Gravel (1996). Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum.Molec.Genet. 5(12):1867-1874.
  25. L.Dupuis, A.Leon del Rio, D.Leclerc, E.Campeau, L.Sweetman, J-M.Saudubray, G.Herman, K.M.Gibson, R.A. Gravel (1996). Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency. Hum.Mol.Genet.5(7):1011-1016.
  26. E.Campeau, D.Watkins, G.A.Rouleau, R.BaBul, J.A.Buchanan, W.Meschino, V.M.Der Kaloustian (1995). Linkage analysis of the nail-patella syndrome. Am.J.Hum.Genet. 56(1):243-247.

Poster Presentations (2013 – PRESENT)

  1. E.Campeau, S.Pradhananga, D.Srinivasan, A.Bapat, P.Truex, D.Odink, A.Sehnert, S.Das (2026). “A Potent Serum and Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitor is Protective in a Model of CKMD. Presented at AHA Basic Cardiovascular Sciences in July 2026.
  2. E.Campeau, S.Pradhananga, D.Srinivasan, D.Labit, K.Frias Boligan, M.Vidal, D.Odink, P.Truex, A.Sehnert, S.Das (2025). The serum and glucocorticoid regulated kinase 1 (SGK1) inhibitor THRV-1268 attenuates hallmarks of heart failure by reducing inflammation and fibrosis beyond sodium/glucose cotransporter 2 inhibition. Moderated e-poster at the American Heart Association Annual Meeting.
  3. S.Pradhananga, W.Salvail, E.Campeau, D.Srinivasan, M.Vidal, P.Truex, D.Odink, S.Das, A.Sehnert (2025). THRV-1268, a potent and selective serum and glucocorticoid regulated kinase (SGK1) inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure. Moderated e-poster at the American Heart Association Annual Meeting.
  4. D.Srinivasan, S.Pradhananga, M.Vidal, E.Campeau, D.Odink, A.Sehnert, S.Das (2025). Small molecule inhibitors of serum glucocorticoid kinase 1 (SGK1) prevent cardiac structural and functional decline induced in a transverse aortic constriction (TAC) model. Moderated e-poster at the American Heart Association Annual Meeting.
  5. S.Das, S.Pradhananga, E.Campeau, D.Srinivasan, M.Vidal, D.Labit, K.Frias Boligan, M.Blanchette, D.Odink, A.Sehnert (2025). THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure. Moderated e-poster at the European Society of Cardiology Annual meeting.
  6. D.Labit, M.Khalifa, S.Hewgill, M.Vidal, D.Srinivasan, D.Odink, S. Das, E.Campeau (2024). Serum and Glucocorticoid Regulated Kinase 1 (SGK1) Inhibition Induces Anti-Fibrotic and Anti-Inflammatory Responses: Relevance to Cardiac Fibrosis. American Heart Association Annual meeting.
  7. S.Pradhananga, O.Shilova, S.Hewgill, E.Campeau, D.Srinivasan, P.Senese, M.Gralinski, M.Zammit, P.Sager, S.Das (2024), Serum Glucocorticoid Regulated Kinase 1 (SGK-1) Inhibitor Reduced Hypertension in a Salt-Sensitive Hypertension Model of Heart Failure with Preserved Ejection Fraction. American Heart Association Annual meeting.
  8. Five abstracts accepted for poster presentations to the American Association for Cancer Research (2024) that were withdrawn for strategic decision.
  9. D.Labit, L.D.Huyn, M.Khalifa, P.F.Truex, D.Odink, A.Di Cristofano, E.Campeau (2023). The SGK1 Inhibitor THRV-1257 Induces Robust Tumor Regression and Overcomes Resistance to Standard of Care Dabrafenib Plus Trametinib in a Mouse Model of Anaplastic Thyroid Cancer (ATC) with BRAF V600E Mutation. American Thyroid Association annual meeting (Poster link).
  10. D.Labit, S.Pradhananga, M.Khalifa, E.Blackburn, N.Sajid, M.Vidal, D.Odink, E.Campeau (2022). Development of novel inhibitors of the serum/glucocorticoid induced kinase (SGK) family to address limitations of AKT/PI3K/mTOR inhibitors in breast cancer. San Antonio Breast Cancer Symposium (Poster link).
  11. P.Aftimos, M.Oliveira, K.Punie, V.Boni, E.Hamilton, A.Gucalp, P.Shah, L.Mina, M.de Miguel, P.Sharma, L.Bauman, E.Campeau, S.Attwell, M.Snyder, K.Norek, E.Johnson, A.Czibere, Y.Yu, M.H.Silverman, S.Lakhotia, S.Domchek, J.Litton, M.Robson (2022). A Phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
  12. R.Aggarwal, M.Schweizer, D.Nanus, S.Attwell, E.Campeau, E.Johnson, P.Wegge, L.Bauman, M.H. Silverman, V.Xu, H.Zhu, M.Snyder, S.Lakhotia, J.Alumkal (2022). A Randomized Phase 2b Study of the BET Bromodomain Inhibitor (BETi) ZEN-3694 and Enzalutamide vs. Enzalutamide Monotherapy in Metastatic Castration Resistant Prostate Cancer. ASCO Genitourinary Cancers Symposium. (Poster link).
  13. P.Aftimos, M.Oliveira, K.Punie, V.Boni, E.Hamilton, A.Gucalp, P.Shah, L.Mina, P.Sharma, L.Bauman, E.Campeau, S.Attwell, M.Snyder, K.Norek, A.Czibere, Y.Yu, M.H.Silverman, S.Lakhotia, S.Domchek, J.Litton, M.Robson (2020). PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations. San Antonio Breast Cancer Symposium. (Poster link)
  14. R.Aggarwal, M.T.Schweizer, A.Pantuck, D.Nanus, E.Heath, S.Lakhotia, M.H.Silverman, L.Bauman, M.Snyder, K.Norek, E.Gesner, S.Attwell, E.Campeau, W.Abida, J.J.Alumkal (2019a). Results from a Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer Foundation Retreat. (Poster link)
  15. E.Campeau, M.O’Farrell, M.Snyder, S.Attwell, L.Bauman, K.J.Norek, M.H.Silverman,, S.Smith, P.Wegge, R.Jahagirdar, H.C.Hansen, S.Lakhotia (2019). Evidence of clinical activity of ZEN-3694, a bromodomain and extra-terminal (BET) protein inhibitor, in combination with enzalutamide for treating metastatic castration resistant prostate cancer. Gordon Research Conference on Cancer Genetics and Epigenetics.
  16. R.Aggarwal, W.Abida, M.Schweizer, A.Pantuck, D.Nanus, E.Heath, S.Lakhotia, H.C.Hansen, M.H.Silverman, L.Bauman, M.Snyder, E.Campeau, K.J.Norek, S.Attwell, M.O’Farrell, S.Smith, P.Wegge, R.Jahagirdar, J.J.Alumkal (2019b). A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). AACR Annual Meeting. (Poster link)
  17. S.Attwell, K.J.Norek, C.Calosing, H.C.Hansen, S.Lakhotia, E.Campeau, R.Jahagirdar, E.van der Horst (2019). The BET inhibitor ZEN-3694 blocks multiple tumor immune suppressive factors and has the potential to increase the efficacy of anti-PD1 treatment. Talk and poster, Keystone Symposia on Epigenetics and Human Diseases. (Poster link)
  18. O.A.Kharenko, R.G.Patel, R.Jahagirdar, S.Attwell, C.Calosing, L.Tsujikawa, E.Campeau, S.Lakhotia, H.Hansen (2018). P3-06-07: The BET bromodomain inhibitors ZEN-3694 and ZEN-3309 targets several mechanisms of resistance to endocrine therapies in preclinical models of ER+ breast cancers. San Antonio Breast Cancer Symposium.
  19. S.Attwell, L.Tsujikawa, K.Norek, S.Lakhotia, H.C.Hansen, E.Campeau (2017). The BET Bromodomain Inhibitor ZEN-3694 Modulates the Expression of Checkpoint Receptors and Immune Suppressive Factors in the Blood of mCRPC Patients. Society for Immunotherapy of Cancer. (Poster link)
  20. L.Tsujikawa, K.Norek, C.Calosing, S.Attwell, D.Gilham, N.Sharma, J.Tobin, M.Haager, R.Jahagirdar, S.Lakhotia, H.C.Hansen, E.Campeau (2017). LB-038: Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients. AACR Annual Meeting. (Poster link)
  21. S.Attwell, K.Norek, R.Jahagirdar, C.Calosing, S.Lakhotia, E.Campeau, H.C.Hansen (2016b). The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. (Poster link)
  22. S.Attwell, R.Jahagirdar, K.Norek, C.Calosing, L.Tsujikawa, O.A.Kharenko, R.G.Patel, E.M. Gesner, E.Corey, H.M.Nguyen, S.Lakhotia, H.C.Hansen, E.Campeau (2016a). LB-207: Preclinical Characterization of ZEN-3694, a Novel BET Bromodomain Inhibitor Entering Phase I Studies for Metastatic Castration-Resistant Prostate Cancer. AACR Annual Meeting. (Poster link)
  23. S.Attwell, E.Campeau, R.Jahagirdar, O.A.Kharenko, K.Norek, L.Tsujikawa, C.Calosing, R.G.Patel, E.M.Gesner, S.Lakhotia, et al. (2015). C-86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies. AACR-EORTC meeting.
  24. E.Campeau, J.Wu, E.M.Gesner, O.A.Kharenko, S.Attwell, D.Gilham, S.Wasiak, G.S.Wagner, K.G.McLure, P.R.Young (2013a). RVX-2135 is a novel BET inhibitor that decreases MYC and BCL-2 expression and synergizes with cytarabine to induce apoptosis in acute myeloid leukemia cells. Keystone Symposia on Epigenetic Marks and Cancer Drugs.
  25. E.Campeau, R.Jahagirdar, J.Wu, E.M.Gesner, O.A.Kharenko, R.Yu, S.Attwell, H.C.Hansen, G.S. Wagner, K.G. McLure, P.R. Young. (2013b). LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid leukemia cells. AACR Annual Meeting.
Scroll to Top